Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. - Wikidata - awgldk - TriplyDB

Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.

Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.

http://www.wikidata.org/entity/Q34103347

about

MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment MicroRNAs in multiple myeloma and related bone disease Micro-RNAs, New performers in multiple myeloma bone marrow microenvironment MicroRNAs in B-cells: from normal differentiation to treatment of malignancies Role of microRNAs in hepatocellular carcinoma: a clinical perspective Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell.MicroRNA: important player in the pathobiology of multiple myeloma PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242 Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity.Methylation analysis of the phosphates and tensin homologue on chromosome 10 gene (PTEN) in multiple myeloma.Crosstalk between microRNA30a/b/c/d/e-5p and the canonical Wnt pathway: implications for multiple myeloma therapy Identification of the endosomal sorting complex required for transport-I (ESCRT-I) as an important modulator of anti-miR uptake by cancer cells.In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma Histone demethylase RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia.miR-26a and miR-214 down-regulate expression of the PTEN gene in chronic lymphocytic leukemia, but not PTEN mutation or promoter methylation.Correlation between microRNA‑21 and sprouty homolog 2 gene expression in multiple myeloma MicroRNA-21 promotes proliferation, migration, and invasion of colorectal cancer, and tumor growth associated with down-regulation of sec23a expression.Inhibition of MicroRNA-21 induces apoptosis in dermal fibroblasts of patients with systemic sclerosis.Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo.A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells.DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.Targeting MicroRNAs in Cancer Gene Therapy.Aberrant microRNA expression in multiple myeloma.Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma.Immunologic microenvironment and personalized treatment in multiple myeloma.Emerging pathways as individualized therapeutic target of multiple myeloma.MicroRNA-21 and multiple myeloma: small molecule and big function.Mir-34: a new weapon against cancer?Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities.miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway.Oncogenic and Therapeutic Targeting of PTEN Loss in Bone Malignancies.miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.The role of circulating miRNAs in multiple myeloma.miRNAs in multiple myeloma--a survival relevant complex regulator of gene expression Mir-221/222 are promising targets for innovative anticancer therapy.Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts.MiR-21 is required for anti-tumor immune response in mice: an implication for its bi-directional roles.Downregulation of Sprouty homolog 2 by microRNA-21 inhibits proliferation, metastasis and invasion, however promotes the apoptosis of multiple myeloma cells.

P2860

Q26765477-2366AC41-94E4-441F-A2E4-1F86F2D20FB0 Q26770478-5CACF955-BC11-4E4E-9772-15F450B6D648 Q26823660-C56460D9-7C2F-4730-A214-3BBE06A77D5D Q26824682-54A99F69-1E10-4AE1-B5D3-26C81D6CD845 Q27014034-34EE1903-A2E7-49D4-9E54-35BBBD6A82AA Q28541175-4E1AFDDF-F2F3-406A-9F6E-362B5D734B09 Q33741100-6BC4016A-12CD-4E44-A72E-B6E4E25F2AFF Q33786861-AF767047-DECC-454B-BDBD-A274E8AFFC2D Q33889132-39E8647A-0CF3-4C89-9836-F74A72AB6985 Q33917555-5EB92524-6133-4723-A44D-EB01969456AC Q34103053-A1315854-6F16-4E6E-A273-8C33F9AC9D6F Q34287900-5D31B9A6-847C-428C-8611-A62235133F52 Q35098066-46603208-EB2E-4111-B06E-F6021A656CFD Q35108549-C473F7F4-01F0-42BF-BE24-735E99C3B5F3 Q35176062-968C7EF6-E00C-4089-98A4-F543D7A56D70 Q35176071-654A8B48-7F14-47B7-8E12-485CE6BCD8A8 Q35388055-F8DDAFDF-C35C-435A-8650-5B4546EED9AD Q36096319-380D8110-3A5D-496F-B4B0-C4E8644AC375 Q36135895-112A80EF-7B2D-43E5-9B80-DF601B57244A Q36254566-947CCAED-06AB-49C0-9D81-50A09E3D278A Q36642951-6F79E7EB-50DA-428B-8B1C-210D29C20AEE Q37597751-8E76F079-E2CC-4330-952A-A35E5DEDEEC8 Q37619866-D3536065-C36A-4FE3-8F09-0566B9366289 Q37628264-6DEB0CEF-06DB-47FC-8644-8F87CAAE4AF1 Q38099048-4F7DA8BC-AED5-46FC-AD16-5BF70C7D62EF Q38108387-38CBD74C-86C3-498C-823C-A962D797B75C Q38108390-D3113230-634E-4E9B-8A4A-90A19EDDA45C Q38112176-CF9B4F62-0F3B-45EB-96E6-9342D0D8F174 Q38224963-184DC739-C8AB-4E5A-B095-A5399919066E Q38253374-5374A88C-A451-4FBB-A21D-25900C65C057 Q38299932-AF45A1AF-B128-4F74-B1B5-95DCDF31CB35 Q38360083-FB07CC56-EC9D-4703-8B28-DAA4DEF9D66B Q38379348-BB47618E-DB37-49E0-895E-71712AD21DB5 Q38476564-8A4FE4E1-4724-45F4-92D2-9BE1C2AEFC3F Q38647786-C23CAB46-AB47-46C6-A942-975ECF123176 Q38673891-1D6225FC-9276-4411-AEAF-54D9C0D0E394 Q38767024-7838DBA9-6763-4794-8242-E0384C64248D Q38854653-707C33E6-87CE-421D-ABE2-CE0A1F5422FE Q38873955-71DDF771-9E98-451E-8464-013302F5CF5C Q38892834-B78D114C-DB26-4F69-BB20-627E613CBF41

P2860

Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.

http://www.wikidata.org/entity/Q34103347

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.

@ast

Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.

@en

Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.

@nl

type

label

Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.

@ast

Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.

@en

Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.

@nl

prefLabel

Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.

@ast

Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.

@en

Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.

@nl

P1433

Q34103347-C1215869-572A-45FD-B512-C3650DF7D2A9

P1476

Q34103347-8BE2D58C-2EE7-413E-AC14-9372F59ECF76

P2093

Q34103347-0E64FB30-6BEB-4C99-8D95-068C1CC5D1BD

Q34103347-1B4B6E7A-0113-42CE-8F7C-E0EE3532DE22

Q34103347-1E45F810-1307-43F2-9EC5-9CF1DA468C1E

Q34103347-8663617D-A711-48E9-83DB-800427E88924

Q34103347-88F661DA-3FAA-4182-8619-F58FA8E8A07B

Q34103347-9C206EC4-43DA-45F6-95C7-8A3C391E974A

Q34103347-B8297E20-3323-49D6-B29D-2AE34FD32BF5

Q34103347-C10ACEC5-E2DA-42C8-AD83-7B449086056B

P2860

Q34103347-074989DE-0046-4B0D-894F-4E25D2EFA2CE

Q34103347-0845F903-69E2-4C3E-9562-F6F96607F7B8

Q34103347-11532BA2-1B67-449C-AE61-508F5544140E

Q34103347-13AA6BBB-F098-4630-A732-0F87DD6A445B

Q34103347-19159FC7-EB91-43B6-B264-D2B9AFCD18AA

Q34103347-19A522E6-69E4-4591-890A-338D136861CD

Q34103347-1BF3EBFD-7F42-47C8-B830-647E91C49939

Q34103347-1E17E949-C321-45F9-B77D-FDF2F04CD294

Q34103347-2326DB68-DA3D-4D93-9812-2BF666CF3799

Q34103347-25C1BA89-BCD3-4B5B-9DA9-EAB507AFFD3D

P304

Q34103347-6E0766AC-D756-4C38-99DC-B31AB48E8C21

P31

Q34103347-D1B1BE14-0E89-4461-B0F3-44FC44B837D7

P356

Q34103347-F1DDE59C-1210-4A63-8D9A-54CE89CA67CC

P407

Q34103347-905E1A93-6605-4307-AD1E-18B5AF32B7BE

P433

Q34103347-30B88D80-5CF9-4462-BB40-76D702D61374

P478

Q34103347-41F99E19-A168-42D5-A12F-90209EC6A351

P50

Q34103347-14F5303D-84C7-4068-9776-4825A5793929

Q34103347-5BC3857A-ED8D-4453-BBFB-3C858DD511B5

Q34103347-87581815-8411-4C3F-9DD4-22A07CCCC663

Q34103347-91DD426D-AD83-4C48-91CB-20622EC8323A

Q34103347-AAFADB22-B85C-4D52-8B02-37257DCA9D36

P577

Q34103347-094AAA6B-A2BF-459B-98B1-EAE84140E3E0

P5875

Q34103347-04F6C9A9-8646-470A-AA84-7F98E0DF2781

P698

Q34103347-17D8E417-50C0-4711-ABC3-D8FDCF76A267

P932

Q34103347-1F6AC8B4-22B3-46D3-92A5-ED4CAE76E589

P356

1078-0432.CCR-12-3325

P1433

Clinical Cancer Research

P1476

Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.

@en

P2093

Annamaria Gullà

http://www.w3.org/2001/XMLSchema#string

Emanuela Leone

http://www.w3.org/2001/XMLSchema#string

Maria T Di Martino

http://www.w3.org/2001/XMLSchema#string

Nicola Amodio

http://www.w3.org/2001/XMLSchema#string

Nikhil C Munshi

http://www.w3.org/2001/XMLSchema#string

Pierfrancesco Tassone

http://www.w3.org/2001/XMLSchema#string

Pierosandro Tagliaferri

http://www.w3.org/2001/XMLSchema#string

Umberto Foresta

http://www.w3.org/2001/XMLSchema#string

P2860

A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma

PTEN regulation of ERK1/2 signaling in cancer

Oncomirs - microRNAs with a role in cancer

MicroRNAs: genomics, biogenesis, mechanism, and function

The mammalian anti-proliferative BTG/Tob protein family

Causes and consequences of microRNA dysregulation in cancer

MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand

MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.

OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma.

Targeting microRNAs in cancer: rationale, strategies and challenges.

P304

2096-2106

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-12-3325

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Antonio Giordano

Eugenio Morelli

Kenneth C Anderson

P577

2013-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235750430

http://www.w3.org/2001/XMLSchema#string

P698

23446999

http://www.w3.org/2001/XMLSchema#string

P932

4147955

http://www.w3.org/2001/XMLSchema#string